Credit Suisse analyst Alethia Young maintained a Buy rating on Agios Pharma (NASDAQ: AGIO) yesterday and set a price target of $95. The company’s shares closed yesterday at $81.65.
According to TipRanks.com, Young is a 2-star analyst with an average return of 0.5% and a 43.2% success rate. Young covers the Healthcare sector, focusing on stocks such as Alexion Pharmaceuticals, Sarepta Therapeutics, and Coherus Biosciences.
Currently, the analyst consensus on Agios Pharma is Strong Buy and the average price target is $94.60, representing a 15.9% upside.
In a report issued on May 6, Cowen & Co. also maintained a Buy rating on the stock.
Find more picks by Best Performing Analysts >>
Based on Agios Pharma’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $90.83 million. In comparison, last year the company had a GAAP net loss of $66.17 million.
Based on the recent corporate insider activity of 59 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AGIO in relation to earlier this year. Most recently, in February 2018, Kaye Foster-Cheek, a Director at AGIO bought 2,200 shares for a total of $104,126.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.
